OCU400 Low Dose + OCU400 Med Dose + OCU400 High Dose + OCU400 Second Eye Dosing
Phase 1/2Active 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Retinitis Pigmentosa
Conditions
Retinitis Pigmentosa, Leber Congenital Amaurosis
Trial Timeline
Jan 24, 2022 → Mar 1, 2027
NCT ID
NCT05203939About OCU400 Low Dose + OCU400 Med Dose + OCU400 High Dose + OCU400 Second Eye Dosing
OCU400 Low Dose + OCU400 Med Dose + OCU400 High Dose + OCU400 Second Eye Dosing is a phase 1/2 stage product being developed by Ocugen for Retinitis Pigmentosa. The current trial status is active. This product is registered under clinical trial identifier NCT05203939. Target conditions include Retinitis Pigmentosa, Leber Congenital Amaurosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05203939 | Phase 1/2 | Active |
Competing Products
20 competing products in Retinitis Pigmentosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3 | Sumitomo Pharma | Phase 1/2 | 41 |
| AGN-151597 | AbbVie | Phase 1/2 | 41 |
| CPK850 | Novartis | Phase 1/2 | 41 |
| Valganciclovir + Ganciclovir | Roche | Phase 3 | 77 |
| Valganciclovir | Roche | Pre-clinical | 23 |
| Foscarnet sodium + Ganciclovir | Roche | Phase 1 | 33 |
| Ganciclovir | Roche | Phase 1 | 33 |
| Ganciclovir | Roche | Pre-clinical | 23 |
| Ganciclovir | Roche | Phase 2 | 52 |
| Ganciclovir | Roche | Pre-clinical | 23 |
| Ganciclovir | Roche | Pre-clinical | 23 |
| Zidovudine + Sargramostim + Ganciclovir | Roche | Pre-clinical | 23 |
| Zidovudine + Ganciclovir | Roche | Pre-clinical | 23 |
| Ganciclovir | Roche | Pre-clinical | 23 |
| Interferon beta-1b + Ganciclovir | Roche | Pre-clinical | 23 |
| Ganciclovir | Roche | Pre-clinical | 23 |
| Ganciclovir | Roche | Pre-clinical | 23 |
| Ganciclovir | Roche | Phase 3 | 77 |
| Valganciclovir | Roche | Phase 3 | 77 |
| Cidofovir + Probenecid | Gilead Sciences | Pre-clinical | 22 |